	US 11,986,489 B2
	Method of treating a disease using a glycolytic dependent compound
James Galloway, Bridgewater, NJ (US); Tamara Byk-Tennenbaum, Kiryat Ono (IL); Erez Ilan, Kibbutz Netzer Sereni (IL); Lior Weissman, Nes-Ziona (IL); Sivan Doron, Moshav Arugot (IL); and Eve Montia, Rehovot (IL)
Assigned to Ethicon, Inc., Raritan, NJ (US); and Omrix Biopharmaceuticals Ltd., Kiryat Ono (IL)
Filed by Ethicon, Inc., Somerville, NJ (US); and Omrix Biopharmaceuticals Ltd., Rehovot (IL)
Filed on Feb. 4, 2021, as Appl. No. 17/167,428.
Application 17/167,428 is a division of application No. 15/234,177, filed on Aug. 11, 2016, granted, now 10,960,021.
Claims priority of provisional application 62/205,031, filed on Aug. 14, 2015.
Prior Publication US 2021/0154224 A1, May 27, 2021
Int. Cl. A61K 31/717 (2006.01); A61K 31/704 (2006.01); A61L 15/28 (2006.01); A61L 15/44 (2006.01); A61L 24/00 (2006.01); A61L 24/08 (2006.01)

CPC A61K 31/717 (2013.01) [A61K 31/704 (2013.01); A61L 15/28 (2013.01); A61L 15/44 (2013.01); A61L 24/0015 (2013.01); A61L 24/0042 (2013.01); A61L 24/08 (2013.01); A61L 2400/04 (2013.01)]

3 Claims

1. A method of enhancing a destructive, inhibitive, and/or lethal effect of a glycolytic dependent compound towards cancerous cells in a tissue and/or organ in a subject, the method comprising the steps of:

A—targeting the glycolytic dependent compound to the cancerous tissue and/or organ by placing oxidized regenerated cellulose (ORC) and/or oxidized cellulose (OC) in direct connection with one or more cancerous cells in the tissue and/or organ, and

B—administering the glycolytic dependent compound to the subject by a systemic route,

wherein the ORC and/or OC and the glycolytic dependent compound are administered by different administration routes, and wherein the destructive, inhibitive, and/or lethal effect is enhanced as compared to a same dose of the glycolytic dependent compound administered in the absence of ORC/OC contact.